Related Experiment Video

Updated: May 16, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Everolimus dual effects of an area vasculosa angiogenesis and lymphangiogenesis

Raluca Amalia Ceausu1, Anca Maria Cimpean, Ivanka Dimova

  • 1"Victor Babeş" University of Medicine and Pharmacy, Department of Histology, Angiogenesis Research Center Timisoara, Piata Eftimie Murgu nr. 2, 300041, Timisoara, Timis, Romania. ancacimpean1972@yahoo.com

In Vivo (Athens, Greece)
|December 15, 2012
PubMed

Insights

Everolimus, used for cancer treatment, may unexpectedly promote lymphangiogenesis. This study observed increased lymphatic vessel development in chick embryos treated with everolimus.

Area of Science:

  • Oncology
  • Vascular Biology
  • Molecular Biology

Background:

  • Everolimus is approved for treating astrocytoma, kidney, and pancreatic cancers.
  • It inhibits tumor cell growth, proliferation, and angiogenesis.
  • Its effects on early-stage normal vasculogenesis, angiogenesis, and lymphangiogenesis are unknown.

Purpose of the Study:

  • To investigate the effects of everolimus on normal vasculogenesis, angiogenesis, and lymphangiogenesis.
  • To explore the potential role of everolimus in activating lymphangiogenesis.

Main Methods:

  • Utilized the chick chorioallantoic membrane model.
  • Treated the area vasculosa with everolimus.
  • Assessed intravascular pillar development.
  • Evaluated the expression of Prox1, podoplanin, vascular endothelial growth factor C (Vegf-C), and vascular endothelial growth factor receptor 3 (Vegfr-3).

Main Results:

  • Everolimus treatment led to increased development of intravascular pillars.
  • An active lymphangiogenic response was observed.
  • Upregulation of Prox1, podoplanin, Vegf-C, and Vegfr-3 expression was noted on day 4 in the treated group.

Conclusions:

  • Everolimus may play a role in activating lymphangiogenesis.
  • Further research is needed to understand the implications of everolimus-induced lymphangiogenesis.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...